Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
endometrial cancer
Biotech
BioNTech, SynOx plot paths to FDA as tumor trials hit goals
BioNTech is lining up a challenge to AstraZeneca and SynOx is planning to enter a field served by companies including Daiichi.
Nick Paul Taylor
Apr 13, 2026 5:10am
GSK CEO’s ‘scientific courage’ propels ADC toward ph. 3 tests
Apr 12, 2026 10:10am
Genmab discards ADC from $1.8B ProfoundBio buy
Sep 16, 2025 10:33am
Endometrial cancer data on Genmab's Elahere rival beat forecast
May 23, 2025 9:22am
Capitalizing on ADC frenzy, ProfoundBio attracts $112M series B
Feb 13, 2024 7:00am
